Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet. 2003; 4:257–291.
24 24. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, Manning AK, Florez JC, Wilson PW, D'Agostino RB, Sr., Cupples LA. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008; 359:2208–2219.
25 25. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, Kathiresan S. Genome‐wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018; 50:1219–1224.
26 26. Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, Bourget K, Plagnol V, Field S, Atkinson M, Clayton DG, Wicker LS, Todd JA. Large‐scale genetic fine mapping and genotype‐phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet. 2007; 39:1074–1082.
27 27. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, Lowe CE, Szeszko JS, Hafler JP, Zeitels L, Yang JH, Vella A, Nutland S, Stevens HE, Schuilenburg H, Coleman G, Maisuria M, Meadows W, Smink LJ, Healy B, Burren OS, Lam AA, Ovington NR, Allen J, Adlem E, Leung HT, Wallace C, Howson JM, Guja C, Ionescu‐Tirgoviste C, Simmonds MJ, Heward JM, Gough SC, Dunger DB, Wicker LS, Clayton DG. Robust associations of four new chromosome regions from genome‐wide analyses of type 1 diabetes. Nat Genet. 2007; 39:857–864.
28 28. Smyth DJ, Howson JM, Payne F, Maier LM, Bailey R, Holland K, Lowe CE, Cooper JD, Hulme JS, Vella A, Dahlman I, Lam AC, Nutland S, Walker NM, Twells RC, Todd JA. Analysis of polymorphisms in 16 genes in type 1 diabetes that have been associated with other immune‐mediated diseases. BMC Med Genet. 2006; 7:20.
29 29. Ikramuddin S, Billington CJ, Lee WJ, Bantle JP, Thomas AJ, Connett JE, Leslie DB, Inabnet WB, 3rd, Jeffery RW, Chong K, Chuang LM, Sarr MG, Jensen MD, Vella A, Ahmed L, Belani K, Schone JL, Olofson AE, Bainbridge HA, Laqua PS, Wang Q, Korner J. Roux‐en‐Y gastric bypass for diabetes (the Diabetes Surgery Study): 2‐year outcomes of a 5‐year, randomised, controlled trial. Lancet Diabetes Endocrinol. 2015; 3:413–422.
30 30. Sharma A, Laurenti MC, Dalla Man C, Varghese RT, Cobelli C, Rizza RA, Matveyenko A, Vella A. Glucose metabolism during rotational shift‐work in healthcare workers. Diabetologia. 2017; 60:1483–1490.
31 31. Bouatia‐Naji N, Bonnefond A, Cavalcanti‐Proenca C, Sparso T, Holmkvist J, Marchand M, Delplanque J, Lobbens S, Rocheleau G, Durand E, De Graeve F, Chevre JC, Borch‐Johnsen K, Hartikainen AL, Ruokonen A, Tichet J, Marre M, Weill J, Heude B, Tauber M, Lemaire K, Schuit F, Elliott P, Jorgensen T, Charpentier G, Hadjadj S, Cauchi S, Vaxillaire M, Sladek R, Visvikis‐Siest S, Balkau B, Levy‐Marchal C, Pattou F, Meyre D, Blakemore AI, Jarvelin MR, Walley AJ, Hansen T, Dina C, Pedersen O, Froguel P. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009; 41:89–94.
32 32. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes. 2005; 54:1649–1656.
33 33. Sathananthan A, Man CD, Zinsmeister AR, Camilleri M, Rodeheffer RJ, Toffolo G, Cobelli C, Rizza RA, Vella A. A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations. Clin Endocrinol (Oxf). 2012; 76:212–219.
34 34. Varghese RT, Dalla Man C, Laurenti MC, Piccinini F, Sharma A, Shah M, Bailey KR, Rizza RA, Cobelli C, Vella A. Performance of individually measured vs population‐based C‐peptide kinetics to assess beta‐cell function in the presence and absence of acute insulin resistance. Diabetes Obes Metab. 2018; 20:549–555.
35 35. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C‐peptide levels. Comparison of individual and standard kinetic parameters for C‐peptide clearance. Diabetes. 1992; 41:368–377.
36 36. Robertson RP, Bogachus LD, Oseid E, Parazzoli S, Patti ME, Rickels MR, Schuetz C, Dunn T, Pruett T, Balamurugan AN, Sutherland DE, Beilman G, Bellin MD. Assessment of beta‐cell mass and alpha‐ and beta‐cell survival and function by arginine stimulation in human autologous islet recipients. Diabetes. 2015; 64:565–572.
37 37. Robertson RP, Raymond RH, Lee DS, Calle RA, Ghosh A, Savage PJ, Shankar SS, Vassileva MT, Weir GC, Fryburg DA, Beta cell project team of the foundation for the NIHBC. Arginine is preferred to glucagon for stimulation testing of beta‐cell function. Am J Physiol Endocrinol Metab. 2014; 307:E720–727.
38 38. Shankar SS, Vella A, Raymond RH, Staten MA, Calle RA, Bergman RN, Cao C, Chen D, Cobelli C, Dalla Man C, Deeg M, Dong JQ, Lee DS, Polidori D, Robertson RP, Ruetten H, Stefanovski D, Vassileva MT, Weir GC, Fryburg DA, Foundation for the National Institutes of Health beta‐Cell Project T. Standardized mixed‐meal tolerance and arginine stimulation tests provide reproducible and complementary measures of beta‐cell function: results from the foundation for the National Institutes of Health Biomarkers Consortium Investigative Series. Diabetes Care. 2016; 39:1602–1613.
39 39. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal‐model approach. Diabetes. 1989; 38:1512–1527.
40 40. Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE. Differentiation of diabetes by pathophysiolog, natural history, and prognosis. Diabetes. 2017; 66:241–255.
41 41. Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F, Anckaert E, Weets I, Pipeleers DG, Gorus FK. High frequency of persisting or increasing islet‐specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. Diabetes Care. 2000; 23:838–844.
42 42. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. 1999; 48:150–157.
43 43. Hummel M, Bonifacio E, Schmid S, Walter M, Knopff A, Ziegler AG. Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intern Med. 2004; 140:882–886.
44 44. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis‐prone type 2 diabetes mellitus. Annals of Internal Medicine. 2006; 144:350–357.
45 45. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta‐cell dysfunction. Endocr Rev. 2008; 29:351–366.
46 46. Gosmanov AR, Smiley D, Robalino G, Siqueira JM, Peng L, Kitabchi AE, Umpierrez GE. Effects of intravenous glucose load on insulin secretion in patients with ketosis‐prone diabetes during near‐normoglycemia remission. Diabetes Care. 2010; 33:854–860.
47 47. Umpierrez GE, Smiley D, Robalino G, Peng L, Gosmanov AR, Kitabchi AE. Lack of lipotoxicity effect on {beta}‐cell dysfunction in ketosis‐prone type 2 diabetes. Diabetes Care. 2010; 33:626–631.
48 48. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H. Effect of intensive insulin therapy on beta‐cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel‐group trial. Lancet. 2008; 371:1753–1760.
49 49. Laedtke T, Kjems L, Porksen N, Schmitz O, Veldhuis J, Kao PC, Butler PC. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab. 2000; 279:E520–528.
50 50. Arunagiri A, Haataja L, Cunningham CN, Shrestha N, Tsai B, Qi L, Liu M, Arvan P. Misfolded proinsulin in the endoplasmic reticulum during development of beta cell failure in diabetes. Ann N Y Acad Sci. 2018;.
51 51. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis‐related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009; 32:1626–1631.
52 52.